FOLH1 and prostate carcinoma: In this context, based on findings in prostate cancer (PCA), the prostate specific membrane antigen (PSMA) has become an attractive molecular target for oncological imaging and radionuclide therapy using PSMA PET/CT in TNBC (10, 11).